Basal Ganglia Diseases

• 

  Subject Areas on Research

  • A magnetic resonance imaging study of putamen nuclei in major depression. 
  • A pilot study of a structured interview addressing sexual function in men with schizophrenia. 
  • A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. 
  • Association between functional impairment, depression, and extrapyramidal signs in neuroleptic-free patients with Alzheimer disease. 
  • Background factors and clinical symptoms of major depression with silent cerebral infarction. 
  • Biotin-responsive basal ganglia disease: case report and review of the literature. 
  • Clinical and molecular phenotype of Aicardi-Goutieres syndrome. 
  • Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. 
  • Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. 
  • Cortico-striatal representation of time in animals and humans. 
  • Differential diagnosis of Parkinson's disease and the parkinsonism plus syndromes. 
  • Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. 
  • Extrapyramidal side-effects of antipsychotics in a randomised trial. 
  • Implications of atypical antipsychotic prescribing in the intensive care unit. 
  • In vivo quantitation of basal ganglia and thalamic degenerative changes in two temporal lobectomy patients with affective disorder. 
  • Low-dose droperidol is not devoid of serious side effects. 
  • Methodological issues in negative symptom trials. 
  • Neuroanatomical substrates of depression in the elderly. 
  • Neurological signs in congenital iodine-deficiency disorder (endemic cretinism). 
  • Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. 
  • Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. 
  • Pharmacotherapy of impaired affect in recovering schizophrenic patients. 
  • Postasphyxial encephalopathy in term infants. Sonographic demonstration of increased echogenicity of the thalamus and basal ganglia. 
  • Radiologic correlates of antidepressant-induced delirium: the possible significance of basal-ganglia lesions. 
  • Rapid alterations in corticostriatal ensemble coordination during acute dopamine-dependent motor dysfunction. 
  • Regional metabolic changes in the pedunculopontine nucleus of unilateral 6-hydroxydopamine Parkinson's model rats. 
  • Serotonin syndrome produced by a combination of fluoxetine and lithium. 
  • The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. 
  • The relationship between extrapyramidal signs and cognitive performance in patients with Alzheimer's disease enrolled in the CERAD Study. Consortium to Establish a Registry for Alzheimer's Disease. 
  • Visual event-related potentials in progressive supranuclear palsy, corticobasal degeneration, striatonigral degeneration, and Parkinson's disease. 
  • Zygomycosis of the basal ganglia in intravenous drug users. 
  • [Spontaneous motor activity in mice overloaded with iron-dextran].